NO20004873L - Terapeutiske anvendelser av modne flint (mFLINT) polypeptider eller OPG3, et medlem av TNF reseptor superfamilien - Google Patents
Terapeutiske anvendelser av modne flint (mFLINT) polypeptider eller OPG3, et medlem av TNF reseptor superfamilienInfo
- Publication number
- NO20004873L NO20004873L NO20004873A NO20004873A NO20004873L NO 20004873 L NO20004873 L NO 20004873L NO 20004873 A NO20004873 A NO 20004873A NO 20004873 A NO20004873 A NO 20004873A NO 20004873 L NO20004873 L NO 20004873L
- Authority
- NO
- Norway
- Prior art keywords
- mflint
- flint
- mature
- opg3
- polypeptides
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 2
- 102000015212 Fas Ligand Protein Human genes 0.000 abstract 1
- 108010039471 Fas Ligand Protein Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7985698P | 1998-03-30 | 1998-03-30 | |
US8607498P | 1998-05-20 | 1998-05-20 | |
US9964398P | 1998-09-09 | 1998-09-09 | |
US11257798P | 1998-12-17 | 1998-12-17 | |
US11293398P | 1998-12-18 | 1998-12-18 | |
US11270398P | 1998-12-18 | 1998-12-18 | |
US11340798P | 1998-12-22 | 1998-12-22 | |
PCT/US1999/006797 WO1999050413A2 (en) | 1998-03-30 | 1999-03-30 | THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20004873D0 NO20004873D0 (no) | 2000-09-28 |
NO20004873L true NO20004873L (no) | 2000-11-24 |
Family
ID=27568394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20004873A NO20004873L (no) | 1998-03-30 | 2000-09-28 | Terapeutiske anvendelser av modne flint (mFLINT) polypeptider eller OPG3, et medlem av TNF reseptor superfamilien |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040167074A1 (pt) |
JP (1) | JP2002512006A (pt) |
KR (1) | KR20010042364A (pt) |
CN (1) | CN1303429A (pt) |
AU (1) | AU3369199A (pt) |
BR (1) | BR9909328A (pt) |
CA (1) | CA2324517A1 (pt) |
CZ (1) | CZ20003433A3 (pt) |
EA (1) | EA200001004A1 (pt) |
HU (1) | HUP0102067A2 (pt) |
ID (1) | ID27820A (pt) |
IL (1) | IL138626A0 (pt) |
NO (1) | NO20004873L (pt) |
PL (1) | PL343847A1 (pt) |
TR (1) | TR200002824T2 (pt) |
WO (1) | WO1999050413A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2277925A1 (en) | 1997-01-14 | 1998-07-16 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6.alpha. and 6.beta. |
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
DE69839401T2 (de) | 1997-09-18 | 2009-05-07 | Genentech Inc., San Francisco | Dcr3 polypeptid, ein tnfr homolog |
WO2000037094A2 (en) * | 1998-12-22 | 2000-06-29 | Eli Lilly And Company | Therapeutic applications of flint polypeptides |
AU3739500A (en) * | 1999-03-30 | 2000-10-16 | Eli Lilly And Company | Protease resistant flint analogs |
US6627199B1 (en) | 1999-07-09 | 2003-09-30 | Amgen Inc | Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family |
AU783682B2 (en) | 1999-08-04 | 2005-11-24 | Amgen, Inc. | Fhm, a novel member of the TNF ligand supergene family |
AU6517800A (en) | 1999-08-04 | 2001-03-05 | Amgen, Inc. | Ntr3, a member of the tnf-receptor supergene family |
AU7053000A (en) * | 1999-09-10 | 2001-04-10 | Eli Lilly And Company | Flint compounds and formulations thereof |
EP1225908A2 (en) * | 1999-10-20 | 2002-07-31 | Eli Lilly And Company | Therapeutic applications of flint polypeptides |
AU1915201A (en) * | 1999-12-07 | 2001-06-18 | Eli Lilly And Company | Improving stability of flint through o-linked glycosylation |
WO2002018622A2 (en) * | 2000-08-25 | 2002-03-07 | Human Genome Sciences, Inc. | TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) |
WO2002066050A1 (fr) * | 2001-02-23 | 2002-08-29 | Takeda Chemical Industries, Ltd. | Inhibiteurs de caspase 3 |
ATE438662T1 (de) | 2003-03-26 | 2009-08-15 | Apogenix Gmbh | Verbesserte fc-fusionsproteine |
WO2006072137A1 (en) * | 2005-01-07 | 2006-07-13 | Northern Sydney And Central Coast Area Health Service | Treatment for autoimmune and inflammatory conditions |
WO2008080623A2 (en) | 2006-12-28 | 2008-07-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo |
JP5665739B2 (ja) * | 2008-07-14 | 2015-02-04 | ドイチェス クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum | 炎症性疾患を治療するためのcd95インヒビターの使用 |
CN102671186B (zh) * | 2011-09-19 | 2014-08-06 | 上海市肿瘤研究所 | 促造血的药物组合物及其应用 |
SI2874659T1 (sl) | 2012-07-18 | 2016-11-30 | Apogenix Ag | Inhibitorji signalizirane poti CD95 za zdravljenje MDS |
EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
EP3395355A4 (en) | 2015-12-18 | 2019-06-12 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING CERVICAL EROSION |
WO2017101873A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
US20230032934A1 (en) | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2277925A1 (en) * | 1997-01-14 | 1998-07-16 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6.alpha. and 6.beta. |
US5885800A (en) * | 1997-02-04 | 1999-03-23 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor, TR4 |
AU9013998A (en) * | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
JP2001512667A (ja) * | 1997-08-06 | 2001-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトオーファンレセプターntr−1 |
DE69839401T2 (de) * | 1997-09-18 | 2009-05-07 | Genentech Inc., San Francisco | Dcr3 polypeptid, ein tnfr homolog |
WO1999026977A1 (en) * | 1997-11-24 | 1999-06-03 | Biogen, Inc. | Novel receptors opg-2 |
-
1999
- 1999-03-30 EA EA200001004A patent/EA200001004A1/ru unknown
- 1999-03-30 BR BR9909328-6A patent/BR9909328A/pt not_active Application Discontinuation
- 1999-03-30 TR TR2000/02824T patent/TR200002824T2/xx unknown
- 1999-03-30 HU HU0102067A patent/HUP0102067A2/hu unknown
- 1999-03-30 AU AU33691/99A patent/AU3369199A/en not_active Abandoned
- 1999-03-30 ID IDW20001948A patent/ID27820A/id unknown
- 1999-03-30 IL IL13862699A patent/IL138626A0/xx unknown
- 1999-03-30 PL PL99343847A patent/PL343847A1/xx unknown
- 1999-03-30 CA CA002324517A patent/CA2324517A1/en not_active Abandoned
- 1999-03-30 CN CN99806639A patent/CN1303429A/zh active Pending
- 1999-03-30 CZ CZ20003433A patent/CZ20003433A3/cs unknown
- 1999-03-30 WO PCT/US1999/006797 patent/WO1999050413A2/en not_active Application Discontinuation
- 1999-03-30 JP JP2000541301A patent/JP2002512006A/ja not_active Withdrawn
- 1999-03-30 KR KR1020007010929A patent/KR20010042364A/ko not_active Application Discontinuation
-
2000
- 2000-09-28 NO NO20004873A patent/NO20004873L/no unknown
-
2004
- 2004-03-04 US US10/793,269 patent/US20040167074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20010042364A (ko) | 2001-05-25 |
WO1999050413A3 (en) | 1999-12-02 |
US20040167074A1 (en) | 2004-08-26 |
EA200001004A1 (ru) | 2001-06-25 |
AU3369199A (en) | 1999-10-18 |
NO20004873D0 (no) | 2000-09-28 |
TR200002824T2 (tr) | 2000-12-21 |
CZ20003433A3 (cs) | 2001-10-17 |
BR9909328A (pt) | 2000-12-12 |
PL343847A1 (en) | 2001-09-10 |
ID27820A (id) | 2001-04-26 |
JP2002512006A (ja) | 2002-04-23 |
HUP0102067A2 (hu) | 2001-10-28 |
IL138626A0 (en) | 2001-10-31 |
WO1999050413A2 (en) | 1999-10-07 |
CN1303429A (zh) | 2001-07-11 |
CA2324517A1 (en) | 1999-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20004873L (no) | Terapeutiske anvendelser av modne flint (mFLINT) polypeptider eller OPG3, et medlem av TNF reseptor superfamilien | |
DK39892D0 (da) | Peptid | |
NO914541L (no) | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner | |
DE69533868D1 (de) | Glucagon-ähnliche insulinotrope Peptid-Analoge, Zusammensetzungen und Verwendungsverfahren | |
WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
EP0696206A4 (en) | ADENOVIRUSES CONTAINING MODIFIED FIBROUS PROTEINS | |
NO963742L (no) | Fremgangsmåte til å stimulere hematopoese med hemaglobin | |
SE9802080D0 (sv) | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein | |
JP4739526B2 (ja) | 成長因子相同体zvegf3 | |
DK0689449T3 (da) | Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin | |
Cailleau et al. | Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice | |
FR2704556B1 (fr) | Virus recombinants et leur utilisation en thérapie génique. | |
DK0613499T4 (da) | Humane IT-4-mutantproteiner | |
DK0946162T3 (da) | Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme | |
Layé et al. | Effects of lipopolysaccharide and glucocorticoids on expression of interleukin-1β converting enzyme in the pituitary and brain of mice | |
NO970264L (no) | Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein | |
Dorner et al. | Interleukin-11: biological activity and clinical studies | |
DK0817646T3 (da) | Fremgangsmåder til behandling af inflammation og præparater derfor | |
Pirhonen | Regulation of IL‐18 expression in virus infection | |
DK175837B1 (da) | Interleukin I inhibitorer, fremgangsmåder til fremstilling deraf samt deres anvendelse til terapeutiske formål | |
ATE415978T1 (de) | Sequentielle verabreichung von cpt-11 und apo-2l polypeptid | |
FR2724320B1 (fr) | Nouvel implant pour le traitement des maladies acquises | |
WO2000037094A3 (en) | Therapeutic applications of flint polypeptides | |
DE60137137D1 (de) | Viren gegen hypoxische zellen und gewebe | |
CA2004764A1 (en) | Ancrod proteins, their preparation and use |